Were You Diagnosed With T-Cell Lymphoma After Taking Dupixent?

Dupixent (dupilumab) is a widely prescribed biologic injection made by Regeneron Pharmaceuticals and Sanofi. It is approved to treat atopic dermatitis (eczema), asthma, chronic rhinosinusitis, COPD, and other conditions driven by what doctors call type 2 inflammation. It works by changing how part of the immune system functions.

The lawsuits do not claim Dupixent is ineffective. They focus on a different problem. A growing body of research has reported that patients treated with Dupixent appear to develop cutaneous T-cell lymphoma, a rare cancer of the skin's immune cells, at substantially higher rates than patients who were not treated with the drug. Plaintiffs allege that the manufacturers were aware of this signal and did not adequately warn patients or physicians.

There is a second theory that makes these cases unusual. Early-stage CTCL can look almost identical to eczema, the very condition Dupixent is often prescribed to treat. Lawsuits allege that in some patients the drug may have masked an existing lymphoma, calming the visible symptoms while the cancer progressed undiagnosed, and that in others it may have triggered or accelerated the disease. Either way, the central claim is the same: patients and their doctors were not given the warning they needed to catch the cancer early.

The connection between Dupixent and T-cell lymphoma is supported by a series of peer-reviewed studies, not a single report. Plaintiffs' filings point to multiple epidemiologic analyses that have found a consistent and elevated risk.

To date, several epidemiologic studies have reported a strong and consistent association between Dupixent use and T-cell lymphomas, including the most common CTCL subtypes, mycosis fungoides and Sézary syndrome. The science is still developing and the manufacturers dispute that the drug causes cancer, but the volume and consistency of these findings is what is driving the litigation forward.

The claims center on T-cell lymphomas. The diagnoses most commonly involved are:

CTCL frequently begins with skin changes that can be mistaken for eczema or other rashes, which is part of why it can go undiagnosed. Patients and physicians have reported persistent or worsening patches and plaques on the skin, severe itching, scaly or reddened areas that do not respond to treatment, raised tumors on the skin in later stages, and swollen lymph nodes.

The Dupixent cases have moved quickly from scattered individual filings to a consolidated federal proceeding. Here is the path.

Every state sets a deadline, called a statute of limitations, for filing this kind of claim. The clock is often tied to when you were diagnosed or when you reasonably should have connected your diagnosis to the drug. These deadlines vary by state and can be shorter than people expect. If you wait too long, you can lose the right to file no matter how strong your case is.

Acting early has practical benefits beyond the deadline. It gives your attorney time to gather and preserve medical and pharmacy records, document your Dupixent use and your diagnosis, and position your claim while the litigation is still in its early stages. A free review now costs you nothing and protects your options.

Baker Legal Team represents people across the country in claims against large pharmaceutical and medical device manufacturers. We take these cases on a contingency basis, which means you pay no attorney fees unless we recover compensation for you. Our team handles the legal work, the records, and the deadlines so you can focus on your health.